semaglutide bone density New studies have raised fresh alarms about the popular “weight-loss drug” Ozempic, revealing it may accelerate loss and weaken skeletal health in users. Research published in 2025–2026 shows patients on Semaglutide (Ozempic) linked to fewer

The letter: "Your claims imply that your product is the same as an FDA-approved product when it is not." The letter also said that Hims' website made claims that were "false or misleading," and that the product "misbranded." $HIMS response: "As we've previously stated, our Super Bowl ad did not advertise any one treatment or solution

The mean age was 48.4 years, and 69.1% were female

500 mg of pure L-Carnitine in each serving

Summary: Ozempic (semaglutide) commonly causes nausea and gastrointestinal symptoms, particularly during initial treatment and dose increases, though these effects typically lessen over time as the body adapts

doi: 10.1038/nature02196 61